A Review on Cell and Gene Therapy
Fuente:
Zenodo
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Publié: |
Zenodo
2025
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866902267452456960 |
|---|---|
| author | Radha Virulkar*, Sayali Ganjiwale, Sachin Dighade |
| author_facet | Radha Virulkar*, Sayali Ganjiwale, Sachin Dighade |
| contents | <p><span>With the potential to treat a variety of genetic illnesses, malignancies, and chronic aliments, cell and gene therapy (CGT) is a revolutionary method in contemporary medicine. However, because biological materials are complicated, precision is requiring, and many therapies are highly customized, the production of CGT products is fraught with difficulties. This procedure entails the controlled, scalable, and repeatable isolation, alteration, growth, and delivery of cells or gene. Maintaining product quality, making sure regulations are followed, controlling supply chains, and creating economical manufacturing technique are some of the primary obstacles. Although CGT manufacturing has greatly benefited from advancements in bioprocessing automation, quality control, and cryopreservation, the sector still faces challenged in reaching the scalability, consistency, and cost required for broad clinical use. The present state of CGT production, the technologies influencing its future, and the tactics required to get over current obstacles to the effective commercialization of cell and gene therapies</span><span>.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_14584479 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | A Review on Cell and Gene Therapy Radha Virulkar*, Sayali Ganjiwale, Sachin Dighade Cell therapy, Gene therapy, Viral vector, good manufacturing practices (GMP), Scalability <p><span>With the potential to treat a variety of genetic illnesses, malignancies, and chronic aliments, cell and gene therapy (CGT) is a revolutionary method in contemporary medicine. However, because biological materials are complicated, precision is requiring, and many therapies are highly customized, the production of CGT products is fraught with difficulties. This procedure entails the controlled, scalable, and repeatable isolation, alteration, growth, and delivery of cells or gene. Maintaining product quality, making sure regulations are followed, controlling supply chains, and creating economical manufacturing technique are some of the primary obstacles. Although CGT manufacturing has greatly benefited from advancements in bioprocessing automation, quality control, and cryopreservation, the sector still faces challenged in reaching the scalability, consistency, and cost required for broad clinical use. The present state of CGT production, the technologies influencing its future, and the tactics required to get over current obstacles to the effective commercialization of cell and gene therapies</span><span>.</span></p> |
| title | A Review on Cell and Gene Therapy |
| topic | Cell therapy, Gene therapy, Viral vector, good manufacturing practices (GMP), Scalability |
| url | https://doi.org/10.5281/zenodo.14584479 |